NCT05102110 Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
| NCT ID | NCT05102110 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Origin Sciences |
| Condition | Non Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2021-12-01 |
| Primary Completion | 2027-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 450 participants in total. It began in 2021-12-01 with a primary completion date of 2027-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device. The primary objective of the study is to assess whether significant changes in DNA mutation and methylation associated with Non-colorectal cancers of the Aero-digestive Tract (NCRCADT) can be detected in rectal mucus as shed cells and cell-free DNA (cfDNA) pass through the gut and theoretically can be collected from rectal mucus. Secondary objectives will assess the participant acceptability of the OriCol™ Sampling Device for Pancreatic Ductal Adenocarcinoma, Non-Small Cell Cancer of the Lung, Colorectal Cancer and Urological Cancer controls as well as contributing to a genomic library collating information about rectal mucus.
Eligibility Criteria
Inclusion Criteria: Aged 18 years or over Be able to give voluntary, written informed consent to participate in the study Exclusion Criteria: Participants with symptoms that would make proctoscopic examination inappropriate, including acute anal fissure, symptomatic thrombosed haemorrhoids or obstructing anorectal lesions as determined by rectal examination Participants with a previous history of cancer Participants who have received previously radiotherapy, chemotherapy or immunotherapy for a malignancy.
Contact & Investigator
Mr F McDermott, FRCS
STUDY DIRECTOR
Chief Investigator
Frequently Asked Questions
Who can join the NCT05102110 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Non Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05102110 currently recruiting?
Yes, NCT05102110 is actively recruiting participants. Contact the research team at Ian.Daniels@originsciences.com for enrollment information.
Where is the NCT05102110 trial being conducted?
This trial is being conducted at Exeter, United Kingdom.
Who is sponsoring the NCT05102110 clinical trial?
NCT05102110 is sponsored by Origin Sciences. The principal investigator is Mr F McDermott, FRCS at Chief Investigator. The trial plans to enroll 450 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.